TrialSignal
Clinical trial intelligence report
An Open-label, Ascending Multiple-dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents With Osteogenesis Imperfecta
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT04545554
Status
COMPLETED
Phase
PHASE1
Sponsor
Amgen
Executive brief
Investment-Ready Snapshot
The primary objective of this study is to evaluate the pharmacokinetics (PK) profile following multiple subcutaneous (SC) doses of romosozumab in children and adolescents with Osteogenesis Imperfecta (OI).
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04545554
Indication
Osteogenesis Imperfecta
Modality
monoclonal antibody
Target
Romosozumab, Calcium, Vitamin D
Intervention
Romosozumab, Calcium, Vitamin D
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.